Andrew Powell Joins InterMune As Executive Vice President And General Counsel

Andrew Powell Joins InterMune As Executive Vice President And General Counsel

PR Newswire

BRISBANE, Calif., Sept. 24, 2013

BRISBANE, Calif., Sept. 24, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ:
ITMN) today announced that Andrew Powell has joined InterMune as Executive
Vice President, General Counsel and Corporate Secretary.

(Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

Mr. Powell will be responsible for managing the company's legal affairs. He
will report to Dan Welch, Chairman, Chief Executive Officer and President of
InterMune.

Mr. Welch said, "Andrew brings experience in many areas that are key to
InterMune's future as our Esbriet sales continue to grow globally, and we plan
for anticipated approval and launch of Esbriet in the United States."

Mr. Powell's experience spans two decades of leadership in the life sciences,
most recently as Executive Vice President, General Counsel and Secretary at
Cornerstone Therapeutics. Mr. Powell has practiced law for more than 25 years,
principally in healthcare and biotechnology. He held positions of increasing
responsibility for more than 15 years at the multi-national healthcare company
Baxter, where he was instrumental in a series of transactions that established
Baxter throughout Asia; Mr. Powell led the global law practice at Baxter
Bioscience. Subsequently, he was part of the senior team that repositioned
Collagenex Pharmaceuticals as a leader in dermatology. Mr. Powell then served
as SVP and General Counsel at ImClone Systems, where he helped the company
grow before playing a key role in a successful process that resulted in a sale
to Eli Lilly.

Mr. Powell holds a B.A. from the University of North Carolina at Chapel Hill
and a J.D. from Stanford Law School.

About InterMune

InterMune is a biotechnology company focused on the research, development and
commercialization of innovative therapies in pulmonology and orphan fibrotic
diseases. In pulmonology, InterMune is focused on therapies for the treatment
of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.
Pirfenidone, the only medicine approved for IPF anywhere in the world, is
approved for marketing by InterMune in the EU and Canada as Esbriet^® and is
currently in a Phase 3 clinical trial to support regulatory registration in
the United States. InterMune's research programs are focused on the discovery
of targeted, small-molecule therapeutics and biomarkers to treat and monitor
serious pulmonary and fibrotic diseases.For additional information about
InterMune and its R&D pipeline, please visit http://www.intermune.com/.

SOURCE InterMune, Inc.

Website: http://www.intermune.com
Contact: Jim Goff, InterMune, Inc., 415-466-2228, jgoff@intermune.com